|

safusidenib Clinical Trials

1 actively recruiting trial across 1 location

Also known as: AB-218, DS-1001b

Pipeline

Phase 3: 1

Top Sponsors

  • Nuvation Bio Inc.1

Indications

  • Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted1
  • Astrocytoma, IDH-Mutant, Grade 21
  • Astrocytoma, IDH-Mutant, Grade 41
  • Astrocytoma, IDH-Mutant, Grade 31
  • IDH1-mutant Glioma1

Birmingham, Alabama1 trial

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

University of Alabama

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.